3.2899
price down icon0.60%   -0.0201
 
loading
Precedente Chiudi:
$3.31
Aprire:
$3.34
Volume 24 ore:
265.71K
Relative Volume:
0.45
Capitalizzazione di mercato:
$181.56M
Reddito:
$163.78M
Utile/perdita netta:
$25.88M
Rapporto P/E:
5.0614
EPS:
0.65
Flusso di cassa netto:
$-28.66M
1 W Prestazione:
+1.54%
1M Prestazione:
+11.90%
6M Prestazione:
-41.46%
1 anno Prestazione:
-64.20%
Intervallo 1D:
Value
$3.25
$3.375
Intervallo di 1 settimana:
Value
$3.15
$3.40
Portata 52W:
Value
$2.645
$9.55

Voyager Therapeutics Inc Stock (VYGR) Company Profile

Name
Nome
Voyager Therapeutics Inc
Name
Telefono
857-259-5340
Name
Indirizzo
75 HAYDEN AVENUE, LEXINGTON, MA
Name
Dipendente
172
Name
Cinguettio
@VoyagerTx
Name
Prossima data di guadagno
2025-03-11
Name
Ultimi documenti SEC
Name
VYGR's Discussions on Twitter

Confronta VYGR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VYGR
Voyager Therapeutics Inc
3.2811 181.50M 163.78M 25.88M -28.66M 0.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.11 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
566.60 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.69 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.29 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.60 31.91B 3.81B -644.79M -669.77M -6.24

Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-10 Iniziato Cantor Fitzgerald Overweight
2024-12-02 Iniziato Citigroup Buy
2024-11-29 Ripresa Wedbush Outperform
2024-10-16 Iniziato Leerink Partners Outperform
2024-03-26 Iniziato Guggenheim Buy
2024-03-19 Iniziato H.C. Wainwright Buy
2024-03-07 Iniziato Citigroup Buy
2024-01-02 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-05-10 Iniziato Truist Buy
2023-03-10 Iniziato Oppenheimer Outperform
2021-10-07 Aggiornamento Robert W. Baird Neutral → Outperform
2021-02-26 Downgrade Robert W. Baird Outperform → Neutral
2021-02-03 Downgrade BTIG Research Buy → Neutral
2021-02-03 Downgrade Wedbush Outperform → Neutral
2020-12-24 Downgrade Cantor Fitzgerald Overweight → Neutral
2020-12-23 Downgrade Raymond James Outperform → Mkt Perform
2020-11-11 Downgrade Oppenheimer Outperform → Perform
2020-11-10 Downgrade Raymond James Strong Buy → Outperform
2020-11-10 Downgrade Wells Fargo Overweight → Equal Weight
2020-03-19 Iniziato The Benchmark Company Buy
2020-02-06 Iniziato Oppenheimer Outperform
2018-11-15 Aggiornamento Raymond James Outperform → Strong Buy
2018-09-10 Ripresa BTIG Research Buy
2018-09-10 Downgrade Morgan Stanley Overweight → Equal-Weight
2018-06-04 Iniziato H.C. Wainwright Buy
2018-03-12 Downgrade Evercore ISI Outperform → In-line
2018-03-12 Downgrade Wedbush Outperform → Neutral
2018-02-02 Iniziato Morgan Stanley Overweight
2017-11-28 Ripresa Piper Jaffray Overweight
2017-10-31 Iniziato Robert W. Baird Outperform
2017-10-27 Iniziato Canaccord Genuity Buy
2017-10-23 Reiterato Stifel Buy
2017-10-12 Iniziato Raymond James Outperform
2017-08-17 Iniziato Evercore ISI Outperform
2017-07-28 Ripresa Stifel Buy
Mostra tutto

Voyager Therapeutics Inc Borsa (VYGR) Ultime notizie

pulisher
Jul 24, 2025

How high can Voyager Therapeutics Inc. stock price go in 2025Rapid return acceleration - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

What drives Voyager Therapeutics Inc. stock priceFree Capital Efficiency Planning - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Voyager Therapeutics Inc. stockMarket-leading growth rates - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Is Voyager Therapeutics Inc. a good long term investmentHigh-yield trading alerts - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Voyager Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Why Voyager Therapeutics Inc. stock attracts strong analyst attentionFree Smart Money Stock Analysis - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Voyager Therapeutics’ Promising Alzheimer’s Study: A Potential Game-Changer? - MSN

Jul 22, 2025
pulisher
Jul 21, 2025

Voyager Therapeutics: A High-Conviction Biotech Play in the Tau-Targeting Alzheimer's Revolution - AInvest

Jul 21, 2025
pulisher
Jul 20, 2025

Why did Voyager's net profit surge in Q4 2024 despite high operating expenses? - AInvest

Jul 20, 2025
pulisher
Jul 19, 2025

Does Voyager Therapeutics Inc. stock pay reliable dividendsTrend Based Entry Alerts - beatles.ru

Jul 19, 2025
pulisher
Jul 18, 2025

Baird Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛

Jul 18, 2025
pulisher
Jul 17, 2025

Voyager Therapeutics adds new gene therapy to Alzheimer’s program - BioWorld MedTech

Jul 17, 2025
pulisher
Jul 17, 2025

Baird reiterates Outperform rating on Voyager Therapeutics stock with $18 price target - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Citi Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $11 - 富途牛牛

Jul 17, 2025
pulisher
Jul 17, 2025

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease - GlobeNewswire

Jul 17, 2025
pulisher
Jul 16, 2025

How Voyager Therapeutics Inc. stock performs during market volatilityDaily Top Gainers - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

Voyager Therapeutics Introduces New Program Targeting Genetic Risk Factor of Alzheimer's Disease - 富途牛牛

Jul 16, 2025
pulisher
Jul 16, 2025

Voyager Therapeutics Launches New Gene Therapy Program Targeting APOE for Alzheimer's Disease Treatment - Quiver Quantitative

Jul 16, 2025
pulisher
Jul 16, 2025

Voyager Therapeutics unveils APOE-targeting Alzheimer’s therapy program By Investing.com - Investing.com South Africa

Jul 16, 2025
pulisher
Jul 16, 2025

Voyager Therapeutics unveils APOE-targeting Alzheimer’s therapy program - Investing.com

Jul 16, 2025
pulisher
Jul 16, 2025

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Voyager Therapeutics Inc. stock price move sharplyBreakout Setup Scanner - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Allspring Global Investments Holdings LLC Buys 21,149 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World

Jul 12, 2025
pulisher
Jul 05, 2025

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Buy” from Brokerages - Defense World

Jul 05, 2025
pulisher
Jun 25, 2025

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Rhumbline Advisers - Defense World

Jun 25, 2025
pulisher
Jun 18, 2025

Financial Comparison: Prime Medicine (NYSE:PRME) & Voyager Therapeutics (NASDAQ:VYGR) - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Voyager Therapeutics at H.C. Wainwright: Genetic Innovation in Focus By Investing.com - Investing.com Canada

Jun 17, 2025
pulisher
Jun 11, 2025

Equities Analysts Offer Predictions for VYGR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspecti - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | VYGR Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire

Jun 10, 2025
pulisher
Jun 09, 2025

Millennium Management LLC Sells 60,935 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Squarepoint Ops LLC Decreases Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World

Jun 08, 2025

Voyager Therapeutics Inc Azioni (VYGR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Voyager Therapeutics Inc Azioni (VYGR) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Sandrock Alfred
President and CEO
Apr 02 '25
Sale
3.43
10,885
37,336
430,931
$23.29
price down icon 1.74%
$36.50
price up icon 0.00%
$103.56
price down icon 0.03%
$27.38
price down icon 0.69%
$113.86
price down icon 0.68%
biotechnology ONC
$288.37
price down icon 2.39%
Capitalizzazione:     |  Volume (24 ore):